Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | POR | P16435 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977366 | 0.85 | LPL (0.33) | LPLLIPGHIF1ACXCR2TAAR1 | |
| SCHEMBL19513403 | 0.85 | LPL (0.33) | LPLLIPGHIF1AUCHL1CXCR2 | |
| SCHEMBL23057746 | 0.81 | LPL (0.37) | LPLLIPGHIF1AUCHL1CXCR2 | |
| SCHEMBL31111473 | 0.81 | HSD17B3 (0.37) | LPLLIPGHIF1AUCHL1CXCR2 | |
| SCHEMBL13202158 | 0.81 | CXCR2 (0.47) | LPLLIPGUCHL1CXCR2MAPT | |
| SCHEMBL15450937 | 0.81 | LIPG (0.40) | LPLLIPGHIF1AUCHL1CA1 | |
| SCHEMBL136492 | 0.80 | HPGD (0.35) | HIF1AUCHL1CXCR2 | |
| SCHEMBL21358544 | 0.79 | LPL (0.35) | LPLLIPGCXCR2RXFP1 | |
| SCHEMBL26606881 | 0.79 | HIF1A (0.37) | LPLLIPGHIF1ACXCR2 | |
| SCHEMBL29424563 | 0.78 | LPL (0.38) | LPLLIPGHIF1AMAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230322774-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11702415-B2 | Crystalline hydrate of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322774-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | LPL 4841/4885LIPG 4081/4885HIF1A 884/4885 |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | LPL 4770/4885LIPG 3975/4885HIF1A 1714/4885 |
| US-11702415-B2 | Crystalline hydrate of a JAK inhibitor compound | JAK1, JAK2, JAK3 | LPL 4738/4885LIPG 3871/4885HIF1A 332/4885 |
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | LPL 4738/4885LIPG 3871/4885HIF1A 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.